



DFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

ANTONSSON et al

Atty. Ref.: LCM-3764-153

Serial No. 10/776,245

TC/A.U.: 1646

Filed: February 12, 2004

Examiner: Kam, Chih Min

For: NOVEL COMPOUNDS

* * * * *

January 31, 2007

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

As suggested by 37 C.F.R. 1.97, and in reply to the Examiner's request to resubmit references filed in parent applications, the undersigned attorney brings to the attention of the Patent and Trademark Office the references listed on the attached form PTO/SB/08a. The references indicated by an asterisk (*) will be submitted in a Supplemental Information Disclosure Statement upon receipt by the undersigned.


This is not to be construed as a representation that a search has been made or that no better prior art exists, or that a reference is relevant merely because cited.

The Examiner is requested to initial the attached form PTO/SB/08a and to return a copy of the initialed document to the undersigned as an indication that the attached references have been considered and made of record.


Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____


Leonard C. Mitchard
Reg. No. 29,009

LCM:iff
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO.	SERIAL NO.
	3764-153	10/776,245
	APPLICANT	
	ANTONSSON et al	
	FILING DATE	GROUP
	February 12, 2004	1646

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Stewart et al, "Solid Phase Peptide Synthesis," Pierce Chemical Co., pp. 18-20 (w/appendix).
	Bajusz, "Interaction of Trypsin-like Enzymes with Small Inhibitors," Symposia Biologica Hungarica 25, pp. 277-298, (1984).
	Jackson et al, "Pharmacological Assessment of the Antithrombotic Activity...", J. of Pharm. Exp. Ther., Vol. 261, pp. 546-552 (1992).
	Knabb et al, "IN Vivo Characterization of New Synthetic Thrombin Inhibitor," Thrombosis and Haemostasis, Vol. 67, No. 1, pp. 56-59 (1992).
	Bajusz et al, "Inhibition of Thrombin with H- and Boc-D-Phe-Pro-Agm," Chem. Abs. 99: 205609w (1993).
	Klement et al, "The Effect of Thrombin Inhibitors on Tissue Plasminogen...", Thrombosis and Haemostasis, Vol. 68, No. 1, pp. 64-68 (1992).
	* Märki et al, "The Anticoagulant and Antithrombotic Properties of Hirudins," Thrombosis and Haemostasis, Vol. 64, No. 3, pp. 344-348 (1990).
	Broersma et al, "The Effect of Thrombin Induction Inhibition in a Rat Arterial Thrombosis Model," Thrombosis Research, Vol. 64, pp. 405-412 (1991).
	Persson et al, Thorax, Vol. 47, pp. 993-1000 (1992).
	Salomonson et al, Am. Rev. Resp. Dis., Vol. 146, pp. 1535-1542 (1992).
	Markwardt et al, Biochem. Pharm., Vol. 23, pp. 2247-2256 (1974).
	Malek et al, "Palladium-catalyzed synthesis of Cinnamylamides," J. Org. Chem., Vol. 47, No. 27, pp. 5395-5397 (1982).
	Malek et al, Chem. Abs. 98: 16353 (1983).
	Glusa et al, "The influence of benzamidine derivatives on human platelet function," Thrombosis et Diathesis Haemorrhagica, Vol. 31, pp. 172-178 (1974).
	Anderson and Lok, J. Organic Chem., Vol. 37, p. 3953 (1972).
	Fareed et al, Ann. N.Y. Acad. Sci., Vol. 370, pp. 765-784 (1981).
	Geratz, J.D., "Inhibition of thrombin, plasmin and plasminogen compounds," Thrombosis et Diathesis Haemorrhagica, Vol. 23, No. 3, pp. 486-499 (1970).
	Clement, B., et al; "N-Hydroxylation of the Antiprotozoal Drug Pentamidine Catalyzed by Rabbit Liver Cytochrome P-450 2C3 or Human Liver Microsomes, Microsomal Retroreduction, and Further Oxidative Transformation of the Formed Amidoximes"; Drug Metabolism and Disposition; Vol. 22, No. 3, pp. 486-497 (1994).
	* Chung et al, J. Organic Chem., Vol. 1, pp. 270-275 (1990).
	Clement, B., et al; "Reduction of Amidoxime Derivatives to Pentamidine <i>in vivo</i> "; Arch. Pharm. (Weinheim); Vol. 325, pp. 61-62 (1992).

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Initial this form with next communication to application.